Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report [1]

Journal of Clinical Psychiatry

Volumn 67, Issue 8, 2006, Pages 1307-

  Lin, Shih Ku ^a   Chen, Chih Ken ^b  

^a TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERPROLACTINEMIA; LABORATORY TEST; LETTER; PARANOID SCHIZOPHRENIA; PRIORITY JOURNAL; WEIGHT GAIN;

EID: 33748964966     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0821a     Document Type: Letter

References (8)

1. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004;65:1491-1498
2. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
3. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17
4. Wahl R, Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole [letter]. Am J Psychiatry 2005;162:1542-1543
5. Travis MJ, Burns T, Dursun S, et al. Aripiprazole in schizophrenia: consensus guidelines. Int J Clin Pract 2005;59:485-495
6. Anghelescu I, Wolf J. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report [letter]. J Clin Psychiatry 2004;65:1286-1287
7. Ball MP, Hooper ET, Skipwith DF, et al. Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy. Ann Pharmacother 2005;39:1570-1572
8. Grunder G, Carlsson A. Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-977